OPDIVO? (nivolumab) in Combination with CABOMETYX? (cabozantinib) Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma i
PRINCETON, N.J., & ALAMEDA, Calif.--(BUSINESS WIRE)--?Bristol Myers Squibb?(NYSE: BMY) and?Exelixis, Inc.?(NASDAQ: EXEL) today announced results from new analyses from the pivotal Phase 3 CheckMate -9ER trial, demonstrating clinically meaningful, sustained efficacy benefits as well as quality of life improvements with the combination of?OPDIVO??(nivolumab) and?CABOMETYX??(cabozantinib) compared to sunitinib in the first-line treatment of advanced renal cell carcinoma (RCC). These data will be presented in two posters at the virtual American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancers Symposium from February 11 to 13, 2021 and featured in the Poster Highlights Session on February 13, 2021 from 9:00 a.m. ? 9:45 a.m. EST.
Abstract #308: Nivolumab + cabozantinib (NIVO+CABO) vs. sunitinib (SUN) for advanced renal cell carcinoma (aRCC): outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate -9ER (Motzer, et. al.)
With a median follow-up of two years (23.5 months),?OPDIVO?in combination with?CABOMETYX?continued to show superior progression-free survival (PFS), objective response rate (ORR) and overall survival (OS) versus sunitinib, with a low rate of treatment-related adverse events (TRAEs) leading to discontinuation. No new safety signals were identified with extended follow-up. Across the full study population:
- PFS: The combination doubled median PFS (17.0 months vs. 8.3 months, respectively; HR 0.52; 95% CI: 0.43 to 0.64), the trial?s primary endpoint, compared to sunitinib.
- ORR: Nearly twice as many patients responded to?OPDIVO?in combination with?CABOMETYX?vs. sunitinib (54.8% vs. 28.4%).
- OS:?OPDIVO?in combination with?CABOMETYX?maintained improvements in OS, demonstrating a 34% reduction in the risk of death compared to sunitinib (HR: 0.66; 95% CI: 0.50 to 0.87).
- Disease control rate: In an exploratory analysis, the combination was associated with a disease control rate (including complete response, partial response and stable disease) of 88.2% vs. 69.9% with sunitinib.
- Complete response (CR): The CR rate, also exploratory, for?OPDIVO?in combination with?CABOMETYX?was 9.3% compared to 4.3% with sunitinib.
- TRAE discontinuations: Among patients treated with?OPDIVO?and?CABOMETYX, 6.6% discontinued both agents due to TRAEs, 9.7% discontinued?OPDIVO?only and 7.2% discontinued?CABOMETYX?only.